Affordable Access

Publisher Website

Critical Challenges in Pluvicto Therapy: Incontinent and Anticoagulated Patients.

Authors
  • Crowley, James R1
Type
Published Article
Journal
Journal of Nuclear Medicine Technology
Publisher
Society of Nuclear Medicine
Publication Date
Dec 05, 2023
Volume
51
Issue
4
Pages
279–281
Identifiers
DOI: 10.2967/jnmt.123.266482
PMID: 37963775
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

As molecular therapy continues to grow, unanticipated challenges may arise, requiring the institution's therapeutic team to reevaluate its therapeutic protocol to identify and address potential situations and challenges that may occur. This practical pointer will focus on the novel prostate cancer therapy Pluvicto (177Lu-vipivotide tetraxetan) and 2 unique situations and challenges of treating patients at the Theranostic Center at Carilion Clinic, an outpatient facility dedicated to targeted molecular therapy. © 2023 by the Society of Nuclear Medicine and Molecular Imaging.

Report this publication

Statistics

Seen <100 times